NCT03862716 - Remission Evaluation of a Metabolic Intervention for Type 2 Diabetes With IDegLira | Biotech Hunter

Enrollment

159

Participants

Timeline

Start Date

April 23, 2019

Primary Completion Date

June 15, 2022

Study Completion Date

July 31, 2023

Conditions

Type 2 Diabetes Mellitus

Interventions

DRUG

IDegLira

Dose is titrated to achieve fasting normoglycemia

DRUG

insulin degludec

In those who need additional insulin or who cannot tolerate IDegLira, insulin degludec will be used. Dose is titrated to achieve fasting normoglycemia.

DRUG

Metformin

Dose is titrated to 2000 mg per day or maximal tolerated dose

BEHAVIORAL

Lifestyle Therapy

Lifestyle intervention includes individualized dietary and exercise advice targeting at least 5% weight loss with frequent visits and coaching for goal reinforcement, behavior modification and problem-solving

Trial Locations (8)

T2T 5C7

University of Calgary, Calgary

T6G 2E1

University of Alberta, Edmonton

B3H 1V7

Nova Scotia Health Authority, Halifax

Unknown

McMaster University, Hamilton

N6A 4V2

St. Joseph's Hospital, London

N6G 2M1

Western University, London

L6M 1M1

LMC Manna Research, Oakville

K1Y 4E9

The Ottawa Hospital, Ottawa